We are live on ! Find out more
CCM

Copernicus Capital Management Portfolio holdings

AUM $8.26M
1-Year Est. Return 37.91%
This Fund
S&P 500
This Quarter Est. Return
+39.9%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$91.2M
AUM Growth
+$8.59M
Cap. Flow
-$4.3M
Cap. Flow %
-4.71%
Top 10 Hldgs %
79.32%
Holding
27
New
13
Increased
1
Reduced
4
Closed
9

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$9.69M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$9.02M
3
AMGN icon
Amgen
AMGN
+$7.53M
4
IQV icon
IQVIA
IQV
+$5.42M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$4.75M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$9.7M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.17M
3
CVS icon
CVS Health
CVS
+$7.71M
4
MCK icon
McKesson
MCK
+$6.9M
5
BIIB icon
Biogen
BIIB
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZTS icon
26
Zoetis
ZTS
$31.6B
– –
-30,125
Closed -$3.54M
SWAV
27
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-50,000
Closed -$1.66M
1
2

Similar funds

AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Copernicus Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Copernicus Capital Management held 27 positions worth $91.2M, up 10% from $82.6M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Copernicus Capital Management withdrew a net $4.3M in Q2 2020, closing 9 positions and reducing 4 holdings. Its most notable exit was Cigna, an estimated $9.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Copernicus Capital Management opened a new position in AbbVie worth $10.8M.

  • Copernicus Capital Management's largest Q2 2020 buy was AbbVie: 110,000 shares worth $10.8M.
  • Copernicus Capital Management added most to Arena Pharmaceuticals Inc in Q2 2020, an estimated $1.91M increase.
  • Copernicus Capital Management's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $8.17M.
  • Copernicus Capital Management fully exited Cigna in Q2 2020, selling an estimated $9.7M.
  • Copernicus Capital Management's ten largest holdings make up 79% of its $91.2M portfolio in Q2 2020.
  • Copernicus Capital Management opened 13 new positions and closed 9 in Q2 2020.
  • Copernicus Capital Management's portfolio value rose 10% quarter-over-quarter to $91.2M.

Based on Copernicus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.